• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » ElectroCore launches gammaCore handheld VNS in US

ElectroCore launches gammaCore handheld VNS in US

July 18, 2017 By Fink Densford

ElectroCore Logo

Neuroscience tech developer ElectroCore said today it launched its gammaCore non-invasive vagus nerve stimulator, designed for the acute treatment of pain associated with episodic cluster headaches in adult patients, in the US.

The Basking Ridge, N.J.-based company touted the device as the 1st non-invasive, hand-held vagus nerve stimulation device for the reduction of pain. The system is designed to be applied to the neck and applies a patented electrical stimulation through the skin to activate the vagus nerve.

“We are proud to bring gammaCore to the U.S. market, as it provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition. The commercial launch also signifies an important milestone for electroCore, marking the 1st marketed product for the company in the U.S.,” CEO Francis Amato said in a press release.

The device won FDA approval in April, and has also won CE Mark approval in the European Union, the company said.

Late last month, MassDevice.com spoke to ElectroCore CEO Amato about the gammaCore device, its slated launch in the US and how the device differs from other VNS therapy systems

Filed Under: Business/Financial News, Neuromodulation/Neurostimulation Tagged With: electroCore

More recent news

  • Zimmer Biomet, Think Surgical extend exclusive distribution agreement
  • Cambridge Heartwear inks £184M deal to supply NHS with portable ECG monitors
  • J&J, Smith+Nephew plans for ortho megamerger reportedly fall through
  • California and Massachusetts still reign as top US medtech headquarters locations
  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy